Inge Dierynck

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. pmc TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors
    Inge Dierynck
    Tibotec BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
    Antimicrob Agents Chemother 55:5723-31. 2011
  2. doi request reprint Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis
    Erkki Lathouwers
    Tibotec BVBA, Beerse, Belgium
    Antivir Ther 16:99-108. 2011
  3. doi request reprint Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data
    Johan Vingerhoets
    Tibotec BVBA, Mechelen, Belgium
    AIDS Res Hum Retroviruses 26:621-4. 2010
  4. doi request reprint In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients
    Inge Dierynck
    Tibotec BVBA, Mechelen, Belgium
    Antivir Ther 15:1161-9. 2010
  5. ncbi request reprint Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase
    Wim G Verschueren
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, B 2800 Mechelen, Belgium
    J Med Chem 48:1930-40. 2005
  6. doi request reprint Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients
    Sandra De Meyer
    Tibotec BVBA, Mechelen, Belgium bJanssen Cilag BV, Amsterdam, The Netherlands
    AIDS 23:1829-40. 2009
  7. doi request reprint Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application
    Bart Kesteleyn
    Janssen Infectious Diseases, A Division of Janssen Pharmaceutical Companies of Johnson and Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium
    Bioorg Med Chem Lett 23:310-7. 2013
  8. pmc Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier
    Inge Dierynck
    Tibotec BVBA, Mechelen, Belgium
    J Virol 81:13845-51. 2007

Collaborators

Detail Information

Publications8

  1. pmc TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors
    Inge Dierynck
    Tibotec BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium
    Antimicrob Agents Chemother 55:5723-31. 2011
    ....
  2. doi request reprint Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis
    Erkki Lathouwers
    Tibotec BVBA, Beerse, Belgium
    Antivir Ther 16:99-108. 2011
    ..The primary outcome measure was non-inferiority of DRV/r versus LPV/r (HIV type-1 [HIV-1] RNA<50 copies/ml). Here, a detailed 96-week resistance analysis is presented...
  3. doi request reprint Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data
    Johan Vingerhoets
    Tibotec BVBA, Mechelen, Belgium
    AIDS Res Hum Retroviruses 26:621-4. 2010
    ..60%, respectively). ETR was equally effective in suppressing viral replication in patients infected with HIV-1 subtype B or various HIV-1 non-B subtypes...
  4. doi request reprint In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients
    Inge Dierynck
    Tibotec BVBA, Mechelen, Belgium
    Antivir Ther 15:1161-9. 2010
    ....
  5. ncbi request reprint Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase
    Wim G Verschueren
    Tibotec BVBA, Generaal de Wittelaan L 11B 3, B 2800 Mechelen, Belgium
    J Med Chem 48:1930-40. 2005
    ....
  6. doi request reprint Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients
    Sandra De Meyer
    Tibotec BVBA, Mechelen, Belgium bJanssen Cilag BV, Amsterdam, The Netherlands
    AIDS 23:1829-40. 2009
    ....
  7. doi request reprint Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application
    Bart Kesteleyn
    Janssen Infectious Diseases, A Division of Janssen Pharmaceutical Companies of Johnson and Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium
    Bioorg Med Chem Lett 23:310-7. 2013
    ....
  8. pmc Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier
    Inge Dierynck
    Tibotec BVBA, Mechelen, Belgium
    J Virol 81:13845-51. 2007
    ..These observations provide a mechanistic explanation for darunavir's potent antiviral activity and high genetic barrier to the development of resistance...